Lifeboat Foundation

A company that makes an implantable brain-computer interface (BCI) has been given the go-ahead by the Food and Drug Administration to run a clinical trial with human patients. Synchron plans to start an early feasibility study of its Stentrode implant later this year at Mount Sinai Hospital, New York with six subjects. The company said it will assess the device’s “safety and efficacy in patients with severe paralysis.” https://www.engadget.com/fda-brain-computer-interface-clinic…ml?src=rss

A company that makes an implantable has been given the go-ahead by the Food and Drug Administration to run a clinical trial with human patients. Synchron plans to start an early feasibility study of its Stentrode implant later this year at Mount Sinai Hospital, New York with six subjects. The company said it will assess the device’s “safety and efficacy in patients with severe paralysis.”

Synchron received the FDA’s green light ahead of competitors like Elon Musk’s. Before such companies can sell BCIs commercially in the US, they need to prove that the devices work and are safe. The FDA will provide guidance for trials of BCI devices for patients with paralysis or amputation during a webinar on Thursday.

Continue reading “FDA clears Synchron’s brain-computer interface device for human trials” »

Synchron has beat rival Neuralink to human trials of its “implantable brain computer interface.”

The chip will be studied in six patients later this year as a possible aid for paralyzed people.

Elon Musk previously used Neuralink’s chip in a monkey, which then played video games with its mind.

Continue reading “This 20-person biotech firm just beat Elon Musk’s Neuralink in getting the OK to test brain chip implants in humans with paralysis” »

Several Clostridium species enriched in children with autism closely interacted with each other and formed a connected group. Clostridia species have been linked with autism via the production of clostridial toxins which can damage the central nervous system, point out the researchers.

Significantly fewer gut bugs linked to neurotransmitter activity.

Children with autism seem to have a distinctive and underdeveloped range and volume of gut bacteria (microbiome) that isn’t related to their diet, suggests a small study published online in the journal Gut.

Continue reading “New Research Finds Children With Autism Have a Distinctive Gut Microbiome” »

A technique developed at Western University to visually iron out the wrinkles and folds in one region of the brain may provide researchers a more accurate picture to understand brain disorders.

Continue reading “Unfolding the hippocampus” »

Thrilled to see Paradromics’ $20M fund raise lead by the talented Dr. Amy Kruse! Paradromics is building a brain computer interface supported by DARPA’s Biologi… See More.

The investment demonstrates confidence in Paradromics as a well-positioned player in the $200 billion BCI therapy market. Last year, Paradromics successfully completed testing of its platform, demonstrating the largest ever electrical recording of cortical activity that exceeded more than 30000 electrode channels in sheep cortex. This recording allowed researchers to observe the brain activity of sheep in response to sound stimuli with high fidelity.

“We are combining the best of neural science and medical device engineering to create a robust and reliable platform for new clinical therapies,” said Paradromics CEO Matt Angle. “This funding round is a validation of both our technology and strategic vision in leading this important developing market.”

Continue reading “Paradromics Raises $20MM in Seed Funding Led by Prime Movers Lab to Advance Brain Computer Interfaces” »

Summary: Study reveals an abundance of the CRMP2 protein in people with schizophrenia. The findings could lead to a blood-based biomarker test for the mental health disorder.

Source: SBPMDI

Scientists at Sanford Burnham Prebys have discovered how levels of a protein could be used in the future as a blood-based diagnostic aid for schizophrenia. The activity of the protein, which is found in both the brain and blood, affects neural connections in human brains and is uniquely imbalanced in people diagnosed with the condition. The research also provides guidance for future analyses into the molecular basis of this serious, disabling mental disorder.

After controlling for factors such as age, sex, handedness, first language, education level, and other variables, the researchers found that those who had contracted COVID-19 tended to underperform on the intelligence test compared to those who had not contracted the virus. The greatest deficits were observed on tasks requiring reasoning, planning and problem solving, which is in line “with reports of long-COVID, where ‘brain fog,’ trouble concentrating and difficulty finding the correct words are common,” the researchers said.

People who have recovered from COVID-19 tend to score significantly lower on an intelligence test compared to those who have not contracted the virus, according to new research published in The Lancet journal EClinicalMedicine. The findings suggest that the SARS-CoV-2 virus that causes COVID-19 can produce substantial reductions in cognitive ability, especially among those with more severe illness.

“By coincidence, the pandemic escalated in the United Kingdom in the middle of when I was collecting cognitive and mental health data at very large scale as part of the BBC2 Horizon collaboration the Great British Intelligence Test,” said lead researcher Adam Hampshire (@HampshireHub), an associate professor in the Computational, Cognitive and Clinical Neuroimaging Laboratory at Imperial College London.

Continue reading “Large study finds COVID-19 is linked to a substantial deficit in intelligence” »

“It’s an extraordinary paper with some extraordinary claims,” says Gray Camp, a developmental biologist at the University of Basel in Switzerland, whose lab last year reported² growing brain organoids that contained a gene common to Neanderthals and humans. The latest work takes the research further by looking at gene variants that humans lost in evolution. But Camp remains sceptical about the implications of the results, and says the work opens more questions that will require investigation.

Humans are more closely related to Neanderthals and Denisovans than to any living primate, and some 40% of the Neanderthal genome can still be found spread throughout living humans. But researchers have limited means to study these ancient species’ brains — soft tissue is not well preserved, and most studies rely on inspecting the size and shape of fossilized skulls. Knowing how the species’ genes differ from humans’ is important because it helps researchers to understand what makes humans unique — especially in our brains.

The researchers, led by Alysson Muotri, a neuroscientist at the University of California, San Diego, used the genome-editing technique CRISPR–Cas9 to introduce the Neanderthal and Denisovan form of a gene called NOVA1 into human pluripotent stem cells, which can develop into any cell type. They cultured these to form organoids, clumps of brain-like tissue, up to 5 millimetres across, alongside normal human brain organoids for comparison.

The result is optogenetics, a mind-controlling technique that’s become one of neuroscience’s most popular tools. Here, scientists use genetic engineering to put different types of algae proteins into the brains of mice. They can then activate a neuron with an implanted fiber optic cable by pulsing certain wavelengths of light. These enhanced brain cells react as they would naturally, generating an electrical signal that’s passed down and interpreted by the mouse’s brain.

Sound familiar?

If an algae protein can artificially allow neurons in the brain to translate light into electrical information, why can’t it do the same for damaged eyes?

Continue reading “How Gene Therapy and Algae Proteins Partially Restored a Blind Man’s Sight” »